

Special Issue

Recent Advances in Therapeutic Cancer Vaccines and their Outcomes

Message from the Guest Editors

Vaccine targets are selected based on several factors, including the tumor microenvironment, which plays an important role in the clinical outcome. Immunotherapies that engage both the adaptive and innate immune systems have the potential to enhance cancer therapeutics. This Special Issue will focus on recent advances in therapeutic cancer vaccines and their outcomes. Specifically, we will look at how the antigen repertoire for vaccine targets can be improved and expanded, consider new developments in vaccine platforms, and explore in situ vaccines. The Special Issue will explore the identification of biomarkers for cancer prognosis and evaluate the mechanism of action and adverse effects associated with antigen targeting. Other potential topics include:

- Combining vaccine platforms with novel immunomodulatory approaches.
- Treatments for overcoming tumor resistance and enhancing clinical efficacy.
- Adoptive transfer therapy and Chimeric Antigen Receptor (CAR) T-cell therapy.
- Vaccine-related therapies and immune checkpoint inhibitors.
- Future perspectives on cancer vaccines.

Guest Editors

Dr. Ruchi Roy

UI Centre for Drug Discovery, College of Pharmacy, University of Illinois Chicago, Chicago, IL 60612, USA

Dr. Sunil Singh

Department of Surgery, Division of Surgical Oncology, University of Illinois Chicago, Chicago, IL 60612, USA

Deadline for manuscript submissions

closed (31 January 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/190019

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).